DM patients who have TET2 mutations may have abnormal regulation of the AMPK-TET2-5hmC pathway and would be more susceptible to cancer, including MDS (Wu et al. 2018; Villivalam et al. 2018). This evidence concerns the gene TET2 and myelodysplastic syndrome.